LY 541850 is claimed from human ionotropic and metabotropic glutamate (mGlu) receptors expressed in non-neuronal cells. LY541850 is a selective orthosteric mGlu2 agonist and mGlu3 antagonist with IC50 values of 0.161 μM and 0.038 μM, respectively[1].
mGluR2|0.161 μM (IC50)|mGluR3|1.05 μM (IC50)
LY 541850 (intraperitoneal injection; 10 mg/kg-300 mg/kg; 15 min prior) induces a concentration-dependent inhibition of the TAP evoked fEPSPs in CA1-SLM in 10-16 week old (EC50 42 nM) in CD-1 mice[1]. LY 541850 (intraperitoneal injection; 10 mg/kg-300 mg/kg; 30 min prior) reduces the increased locomotor activity of phencyclidine and amphetamine in a dose-dependent manner in male ICR mice[1].
